Skip to main content
Equibles
WVE logo

WVE · Wave Life Sciences Ltd.

Track WVE — free

Use WVE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about WVE

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.41 +0.21 (+4.04%) At close · Aug 14
Market Cap
$1.07B
Shares
197.05M

Wave Life Sciences Ltd. Earnings Call Transcripts

Every quarterly earnings call for Wave Life Sciences Ltd. (WVE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼99.2% $285,000 −$39.00M '22 Q3 22-11-10 · $1.24M −$43.71M '22 Q4 23-03-22 ▲638.8% $12.93M −$27.41M '23 Q1 23-05-03 ▲5794.9% $22.11M −$21.10M '23 Q2 23-08-03 ▲17168.1% $49.21M $7.25M '23 Q3 23-11-09 ▲2245.1% $29.06M −$16.26M '23 Q4 24-03-06 ▼3% $12.54M −$31.56M '24 Q1 24-05-09 ▼10.9% $19.69M −$32.92M '24 Q2 24-08-08 ▼26.8% $9.18M −$46.88M '25 Q1 25-05-08 ▼55.8% $8.70M −$50.47M '25 Q2 25-07-30 ▲316.9% $38.25M −$26.09M '26 Q1 26-04-28 LATEST ▼73.9% $2.27M −$69.36M '26 Q2 26-07-30
Conference
Investor event
2026-08-12
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-30
Wave Life Sciences Second Quarter 2026 Earnings Call
Revenue
$2.27M
▼ 73.9% YoY
Diluted EPS
$-0.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-28
Wave Life Sciences Ltd. Q1 FY2026 Earnings Call
Confident tone WVE-007 / INHBE obesity program WVE-006 / AATD RNA editing Liver / NASH opportunity via INHBE
Revenue
$38.25M
▲ 316.9% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Wave Life Sciences Ltd. Q4 FY2025 Earnings Call
Confident tone WVE-007 (INHBE) for obesity WVE-006 for AATD / RNA editing leadership WVE-008 for PNPLA3 liver disease
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-12-08
Wave Life Sciences Ltd. Q3 FY2025 Earnings Call
Confident tone WVE-007 (inhibiting) obesity program 2026 clinical data catalysts WVE-006 AATD RNA editing
Diluted EPS
$-0.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Wave Life Sciences Ltd. Q2 FY2025 Earnings Call
Confident tone WVE-007 / INLIGHT obesity program (INHBE siRNA) Clinical readouts and data cadence FORWARD-53 DMD program (WVE-N531)
Revenue
$8.70M
▼ 55.8% YoY
Diluted EPS
$-0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Wave Life Sciences Ltd. Q1 FY2025 Earnings Call
Confident tone Obesity (WVE-007 / INHBE) AATD / RNA Editing (WVE-006) DMD / WVE-N531
Revenue
$9.18M
▼ 26.8% YoY
Diluted EPS
$-0.29
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Wave Life Sciences Ltd. Q4 FY2024 Earnings Call
Confident tone WVE-007 obesity program and GLP-1 positioning WVE-006 AATD RNA editing program WVE-003 Huntington's disease allele-selective program
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Wave Life Sciences Ltd. Q3 FY2024 Earnings Call
Confident tone Regulatory path and FDA interactions DMD program WVE-N531 (FORWARD-53) Platform differentiation and competition
Diluted EPS
$-0.47
▼ 771.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Wave Life Sciences Ltd. Q2 FY2024 Earnings Call
Confident tone WVE-003 / Huntington's disease (SELECT-HD) WVE-007 / Obesity siRNA WVE-006 / RNA editing for AATD
Revenue
$19.69M
▼ 10.9% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Wave Life Sciences Ltd. Q1 FY2024 Earnings Call
Confident tone RNA editing pipeline / WVE-006 (AATD) GSK collaboration Clinical milestones / upcoming catalysts
Revenue
$12.54M
▼ 3% YoY
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Wave Life Sciences Ltd. Q4 FY2023 Earnings Call
Confident tone INHBE obesity program WVE-006 / AATD RNA editing program DMD / WVE-N531 exon skipping
Revenue
$29.06M*
▲ 2245.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Wave Life Sciences Ltd. Q3 FY2023 Earnings Call
Revenue
$49.21M
▲ 17168.1% YoY
Diluted EPS
$0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Wave Life Sciences Ltd. Q2 FY2023 Earnings Call
Revenue
$22.11M
▲ 5794.9% YoY
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Wave Life Sciences Ltd. Q1 FY2023 Earnings Call
Revenue
$12.93M
▲ 638.8% YoY
Diluted EPS
$-0.27
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-22
Wave Life Sciences Ltd. Q4 FY2022 Earnings Call
Revenue
$1.24M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Wave Life Sciences Ltd. Q3 FY2022 Earnings Call
Revenue
$285,000
▼ 99.2% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Wave Life Sciences Ltd. Q2 FY2022 Earnings Call
Revenue
$375,000
▼ 86.5% YoY
Diluted EPS
$-0.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Wave Life Sciences Ltd. Q1 FY2022 Earnings Call
Revenue
$1.75M
Diluted EPS
$-0.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
Wave Life Sciences Ltd. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Wave Life Sciences Ltd. Q3 FY2021 Earnings Call
Revenue
$36.42M
▲ 955.7% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Wave Life Sciences Ltd. Q2 FY2021 Earnings Call
Revenue
$2.78M
▼ 8.3% YoY
Diluted EPS
$-0.78
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Wave Life Sciences Ltd. Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-04
Wave Life Sciences Ltd. Q4 FY2020 Earnings Call
Revenue
$9.44M*
▲ 293.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Wave Life Sciences Ltd. Q3 FY2020 Earnings Call
Revenue
$3.45M
▲ 17.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Wave Life Sciences Ltd. Q2 FY2020 Earnings Call
Revenue
$3.03M
▼ 60.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Wave Life Sciences Ltd. Q1 FY2020 Earnings Call
Revenue
$4.16M
▲ 37.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
Wave Life Sciences Ltd. Q4 FY2019 Earnings Call
Revenue
$2.40M
▼ 33.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 earnings calls
Key facts CIK 1631574 CUSIP Y95308105 13F (30d) 234 filings 230 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)